Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides

Cristina López-Vicarioa, José Alcaraz-Quilesa, Verónica García-Alonson, Bibiana Riusa, Sung H. Hwangb, Esther Titos, Aritz Lopategia, Bruce D. Hammo, Vicente Arroyoc,d, and Joan Clàriac,e,d

aDepartment of Biochemistry and Molecular Genetics, bLiver Unit, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), cCentro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, and dDepartment of Physiological Sciences I, University of Barcelona, Barcelona 08036, Spain; and eDepartment of Entomology and Comprehensive Cancer Center, University of California, Davis, CA 95616

Contributed by Bruce D. Hammock, December 4, 2014 (sent for review July 25, 2014; reviewed by Karsten Gronert and Steve Watkins)

Soluble epoxide hydrolase (sEH) is an emerging therapeutic target in a number of diseases that have inflammation as a common underlying cause. sEH limits tissue levels of cytochrome P450 (CYP) epoxides derived from omega-6 and omega-3 polyunsaturated fatty acids (PUFA) by converting these into their less active diols. We have explored the metabolic effects of sEH inhibition (t-TUCB) in fat-1 mice with transgenic expression of an omega-3 desaturase capable of enriching tissues with endogenous omega-3 PUFA. These mice exhibited increased CYP1A1, CYP2E1, and CYP2U1 expression and abundance of the omega-3–derived epoxides 17,18-epoxyeicosatetraenoic acid (17,18-EET), 19,20-epoxyeicosapentaenoic acid (19,20-EDP) in insulin-sensitive tissues, especially liver, as determined by LC-ESI-MS/MS. In obese fat-1 mice, t-TUCB raised hepatic 17,18-EET and 19,20-EDP levels and reduced the omega-3–dependent reduction observed in tissue inflammation and lipid peroxidation. t-TUCB also produced a more intense antistatic action in obese fat-1 mice, as revealed by magnetic resonance spectroscopy. Notably, t-TUCB skewed macrophage polarization toward an antiinflammatory M2 phenotype and expanded the interscapular brown adipose tissue volume. Moreover, t-TUCB restored hepatic levels of Atg12-Atg5 and LC3-II conjugates and reduced p62 expression, indicating up-regulation of hepatic autophagy.

The aim of the present study was to investigate the potential metabolic benefits of sEH inhibition in obesity. Specifically, this study addresses the question as to whether sEH inhibition increases the effectiveness of omega-3–derived epoxides in obese adipose tissue and liver in the context of enriched omega-3 tissue content. fat-1 mice with transgenic expression of the Caenorhabditis elegans omega-3 fatty acid desaturase gene represent a useful model to address this question because these mice have abundant tissue omega-3 distribution from their embryonic stage.

cytochrome P450 (CYP) epoxygenases represent the third branch of polyunsaturated fatty acid (PUFA) metabolism (1). CYP epoxygenases add oxygen across one of the four double bonds of PUFA to generate three-membered ethers known as epoxides (1). In the case of arachidonic acid, CYP epoxygenases convert this 6 PUFA into epoxyeicosatrienoic acids (EETs), which act as autocrine or paracrine factors in the regulation of vascular tone, inflammation, hyperalgesia, and organ and tissue regeneration (2, 3). In addition to omega-6s, CYP epoxygenases also convert the omega-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) into novel epoxyeicosatrienoic (EEQs) and epoxydocosapentaenoic (EDPs) acids, respectively (4, 5). These omega-3–derived epoxides also exert salutary actions and are even more effective and potent than omega-6–derived EETs (4–8).

The predicted in vivo half-lives of fatty acid epoxides (EpFA) are in the order of seconds (9), drugs that stabilize their levels by targeting the enzyme soluble epoxide hydrolase (sEH) are currently under investigation. sEH is a cytosolic enzyme with epoxide hydrolase and lipid phosphatase activities that catalyzes the rapid hydrolysis of EETs, EEQs and EDPs by adding water to these EpFA and converting them into inactive or less active 1,2-diols (10). Accordingly, inhibition of sEH exerts beneficial actions in controlling vascular tone, inflammation, and pain, and this strategy has shown its therapeutic potential for long-term use in hypertension, diabetes, renal disease, organ damage, and cardiovascular remodeling (6). The aim of the present study was to investigate the potential metabolic benefits of sEH inhibition in obesity. Specifically, this study addresses the question as to whether sEH inhibition increases the effectiveness of omega-3–derived epoxides in obese adipose tissue and liver in the context of enriched omega-3 tissue content.

Inhibition of sEH by sEH inhibitors (7) limits levels and reinforces the omega-3 (17,18-EEQ) and 19,20-epoxydocosapentaenoic (19,20-EDP) in insulin-sensitive tissues and adipose tissue. This study addresses the question as to whether sEH inhibition regulates autophagy and endoplasmic reticulum stress by providing evidence that omega-3 epoxides and sEH inhibition regulate autophagy and endoplasmic reticulum stress in insulin-sensitive tissues, especially the liver. Therefore, administration of a sEH inhibitor is a promising strategy to prevent obesity-related comorbidities.


Conflict of interest statement: B.D.H. and S.H.H. are authors on a patent held by the University of California on the synthesis of soluble epoxide hydrolase (sEH) inhibitors. B.D.H. founded a company, EioOis, to move these inhibitors to the clinic to treat neuropathic and inflammatory pain. The published and freely available sEH inhibitor was provided by University of California, Davis to the Claria group in Spain along with additional reagents and data. The inhibitor was a key tool to test the hypothesis that the omega-6 and 3 fatty acid epoxides were responsible for biological effects. It is conceivable that use of an sEH inhibitor could be of some benefit to EioOis or GSK, both of which are working to develop these materials clinically. However, numerous publications have been published already implicating these inhibitors in diabetes treatment, and other inhibitors of similar structure and potency are commercially available from Cyma Chemical and Calbiochem. B.D.H. is an author on University of California patents in the area, has stock in EioOis, which has licensed these patents, but has no salary from EioOis.

Significance

Our study demonstrates that stabilization of cytochrome P450 epoxides derived from omega-3 polyunsaturated fatty acids through inhibition of the inactivating enzyme soluble epoxide hydrolase (sEH) exerts beneficial actions in counteracting metabolic disorders associated with obesity. In addition, our study sheds more light on the role of sEH in insulin homeostasis by providing evidence that omega-3 epoxides and sEH inhibition regulate autophagy and endoplasmic reticulum stress in insulin-sensitive tissues, especially the liver. Therefore, administration of a sEH inhibitor is a promising strategy to prevent obesity-related comorbidities.
and throughout their lives (13, 14). This study builds on previous work by our laboratory demonstrating that fat-1 mice replicate the protection against insulin resistance and hepatic inflammation and steatosis observed in obese mice nutritionally enriched with exogenous omega-3 PUFA (13, 15). The results of the present investigation indicate that inhibition of sEH when there is an increased content of omega-3 PUFA exerts a more favorable role in counteracting the metabolic disorders associated with obesity. In addition, our findings expand focus to include the sEH overexpression and modulation of 17,18-EEQ and 19,20-EDP tissue levels by the selective sEH inhibitor, t-TUCB. In response to the HFD, CYP expression was repressed in WT mice, whereas CYP1A1 had constitutive expression of CYP epoxygenases with preference for omega-3 PUFA (Fig. S1E). In response to the HFD, CYP expression was repressed in WT mice, whereas CYP1A1

Results

WT and fat-1 mice had similar body and epididymal white adipose tissue (eWAT) weights under Chow conditions (Fig. S1A). However, fat-1 mice exhibited smaller adipocyte size (Fig. S1B). The administration of a high-fat diet (HFD) resulted in increased adipocyte hypertrophy and extensive positive F4/80 staining (Fig. S1B). HFD-fed mice also displayed enhanced fibrosis (Fig. S1B). Compared with WT, fat-1 mice were more resistant to HFD-induced obesity (body weight: 45.6 ± 0.8 vs. 49.7 ± 1.0 g, P < 0.01; eWAT weight: 1.5 ± 0.1 vs. 1.8 ± 0.1 g, P < 0.01) and showed reduced adipocyte size, macrophage infiltrate, and fibrosis (Fig. S1B). Changes in adiposity, inflammation and fibrosis were confirmed by morphometric analysis and by assessing F4/80 expression by real-time PCR (Fig. S1B). Fat-1 mice also showed reduced monocyte chemoattractant protein-1 (MCP-1) and increased CD206, IL-10, and macrophage galactose-type C-type lectin 1 (MGL1) (Fig. S1C). These results were confirmed in HFD-induced obese mice receiving omega-3 PUFA through the diet (Fig. S1D). No changes in IL-6, IL-1β, arginase-1 (Arg1), resistin-like molecule-α (RELMα), and Ym1 were observed (Fig. S1D). eWAT from both lean WT and fat-1 mice

Fig. 1. Tissue levels of omega-3–derived epoxy metabolites, 17,18-EEQ and 19,20-EDP in fat-1 mice. (A) Schematic diagram of the CYP epoxygenation pathway generating the omega-3 EpFA, 17,18-EEQ, and 19,20-EDP and conversion into their inactive diols by sEH. (B) LC-ESI-MS/MS analysis of 17,18-EEQ and 19,20-EDP levels in eWAT and liver from WT and fat-1 mice. (C) Schematic diagram of the CYP epoxygenation pathway generating omega-6 EpFA (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET) from arachidonic acid (AA) and their inactivation by sEH. (D) LC-ESI-MS/MS analysis of omega-6 EpFA levels in eWAT and liver. Results are mean ± SEM from WT (n = 28) and fat-1 (n = 20) mice. *P < 0.05, **P < 0.01, and ***P < 0.001.

Fig. 2. sEH overexpression and modulation of 17,18-EEQ and 19,20-EDP tissue levels by the selective sEH inhibitor, t-TUCB. (A) Protein expression of sEH in liver and eWAT from WT and fat-1 mice. Densitometry of sEH signals normalized to β-actin is shown on the right. (B) LC-ESI-MS/MS analysis of omega-3 and omega-6 epoxides in liver from HFD-induced obese WT and fat-1 mice receiving t-TUCB (10 μg/mL) for 16 wk. (C) LC-ESI-MS/MS analysis of inactive diols in liver from obese WT and fat-1 mice receiving t-TUCB. (D) Hepatic ratios of active metabolites to inactive diols. (E) Protein expression of sEH in liver and eWAT from obese WT and fat-1 mice receiving t-TUCB. Densitometry of sEH signals normalized to β-actin is shown below. Results are mean ± SEM from WT (n = 28) and fat-1 (n = 20) mice. *P < 0.05, **P < 0.01, and ***P < 0.001.

Fig. 3. Effects of t-TUCB on adipose tissue in obese fat-1 mice. (A) Body weight curves for WT (n = 28) and fat-1 (n = 20) mice receiving a HFD and treated with either placebo (Plb) or t-TUCB for 16 wk. (B) Representative MR images of coronal sections. Total fat volume (C) and iBAT volume (D) assessed by MRI analysis. (E) Representative photomicrographs of adipose tissue sections stained with H&E (Top), F4/80 (Middle), and Sirius red (Bottom) and adipocyte cross-sectional area, Sirius red staining, and F4/80 mRNA expression. (Magnification: 200×) (F) Malondialdehyde (MDA) concentration and MGL1 and RELMα mRNA expression in adipose tissue. Results are mean ± SEM *P < 0.05, **P < 0.01, and ***P < 0.001.
were detected in eWAT and liver (Fig. 1B). Importantly, 17,18-EEO levels were significantly increased in eWAT and liver from fat-1 mice (Fig. 1B). In these tissues, 19,20-EDP was also increased in fat-1 mice and changes in this epoxide reached statistical significance in eWAT (Fig. 1B). Unexpectedly, HFD triggered omega-3-derived epoxides in the liver, especially in WT mice (Fig. 1B). Increased tissue levels of omega-3-derived epoxides were also seen in eWAT and liver from obese WT mice after receiving an omega-3-enriched diet (Fig. S4A). On the other hand, EETs regiosomers (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET), formed from arachidonic acid by CYP epoxidation (Fig. 1C), were also detected in eWAT and especially in liver (Fig. 1D). Hepatic EET levels were also increased by HFD (Fig. 1D), an effect also seen in WT mice receiving an omega-3-enriched diet (Fig. S4B). The fact that omega-3- and omega-6-derived epoxides were more abundant in liver (Fig. 1B and D) was consistent with the presence of a higher content of PUFA in this organ (Fig. S5A). Moreover, although the rate-limiting enzymes involved in long-chain fatty acid desaturation (i.e., Δ5 and Δ6 desaturases) were constitutively expressed in liver, the expression of Δ6 desaturase in eWAT was undetectable and residual at protein (Fig. S5B) and mRNA (Fig. S5C) levels, respectively.

We next sought to establish the role of sEH, the key enzyme in the inactivation of EpFA. Consistent with previous findings, the sEH protein was preferentially expressed in liver (18) and slightly

was induced in fat-1 mice with no changes in CYP2E1 and CYP2U1 (Fig. S1E).

Because—in addition to adipose tissue—the liver plays a pivotal role in metabolic homeostasis, we also examined the hepatic phenotype of fat-1 mice. Consistent with our recent finding that fat-1 mice are protected against HFD-induced hepatic inflammation and steatosis (13), HFD-fed fat-1 mice presented lower serum ALT/AST and reduced F4/80 and Oil Red-O staining (Fig. S2A). Moreover, HFD-fed WT mice exhibited a unique hepatic pattern of CYP expression characterized by up-regulation of CYP1A1, CYP2E1, and CYP2U1 (Fig. S2B). In contrast, only CYP2U1 was up-regulated by HFD feeding in fat-1 mice (Fig. S2B). A distinct pattern of CYP expression in response to HFD was also detected in skeletal muscle (Fig. S2C). Direct comparison of CYP expression among insulin-sensitive tissues revealed that CYP2E1 and CYP2U1 are preferentially expressed in the liver, whereas CYP1A1 appears as the major isoform in muscle (Fig. S2D). The observation that changes in CYP expression in HFD-fed mice in response to omega-3 enrichment are tissue-dependent was confirmed in obese WT mice receiving omega-3 PUFA through the diet (Fig. S3).

Because many CYP epoxigenases can form epoxides converting omega-3 PUFA into biologically active 17,18-EEO and 19,20-EDP metabolites (Fig. 1A), we next analyzed these epoxides by liquid chromatography-electrospray ionization (LC-ESI)-MS/MS. Both EPA-derived 17,18-EEO and DHA-derived 19,20-EDP

---

Fig. 4. Antinflammatory and antisteatotic actions of t-TUCB in livers from obese fat-1 mice. (A) Representative photomicrographs of liver sections stained with F4/80 and histomorphometrical analysis in HFD-induced obese WT and fat-1 mice receiving placebo (Plb) or t-TUCB (10 μg/mL) for 16 wk. (Magnification: 200x.) (B) Hepatic mRNA expression of M1 proinflammatory markers. (C) Hepatic mRNA expression of M2 antiinflammatory markers. (D) Hepatic steatosis assessed by MR spectroscopy. (E) Representative spectra. (F) Liver weight. Results are mean ± SEM from WT (n = 28) and fat-1 (n = 20) mice. *P < 0.05, **P < 0.01, and ***P < 0.001.

---

Fig. 5. t-TUCB regulates in a tissue-specific manner autophagy and ER stress in obese fat-1 mice. (A) Protein expression of Atg7, Atg12-Atg5, LC3-I/II, p62, phosphoIRE1α (p-IRE1α), phosphoERK2α (p-ERK2α), total ERK2α (ERK2α), and GAPDH as determined by 10% SDS/PAGE Western blot in eWAT from WT and fat-1 mice receiving Chow or HFD and treated with t-TUCB (10 μg/mL) for 16 wk. (B) Densitometric analysis of Atg12-Atg5, LC3-I/II, and p62 signals normalized to GAPDH in eWAT. (C) Hepatic protein expression of Atg7, Atg12-Atg5, LC3-I/II, p62, p-IRE1α, p-ERK2α, total ERK2α, and GAPDH. (D) Densitometric analysis of Atg12-Atg5, LC3-I/II, and p62 signals normalized to GAPDH in liver. Results are mean ± SEM from WT (n = 28) and fat-1 (n = 20) mice. *P < 0.05 and **P < 0.01 vs. Chow. *P < 0.05 and **P < 0.001 vs. HFD.
increased by HFD feeding (Fig. 2A). In fat-1 mice, HFD-feeding also increased sEH expression in eWAT (Fig. 2A). Because inhibition of the sEH prevents the inactivation of EpFA by epoxide hydration, we next analyzed the omega-3-derived epoxides in mice treated with the selective sEH inhibitor, trans-4-[4-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy]-benzoic acid (t-TUCB). Administration of t-TUCB to HFD-induced obese mice resulted in increased 17,18-EEQ levels in liver (Fig. 2B) and eWAT (Fig. 2S5) from both WT and fat-1 mice. Tissue levels of 19,20-EDP were increased in livers from fat-1 mice and eWAT from WT animals (Fig. 2B and Fig. 2S5). t-TUCB also increased levels of EETs in liver and eWAT from both WT and fat-1 mice, although the extent of stimulation was less pronounced than that of 19,20-EDP (Fig. 2B and Fig. 2S5). Hepatic levels of 19,20-DHDPd, the inactive or less active 1,2-diol from 19,20-EDP, as well as the respective EETs diols were significantly reduced by t-TUCB in WT mice (Fig. 2C). No changes in diol levels were observed in fat-1 mice (Fig. 2C). Of note, the hepatic ratios of each active epoxide to the corresponding inactive diol were significantly increased by t-TUCB (Fig. 2D). Compared with placebo, t-TUCB did not induce any significant effect on the hepatic and adipose tissue levels of arachidonic acid, DHA and EPA (Table S1). Coincident with previous findings (19), t-TUCB up-regulated hepatic sEH protein expression (Fig. 2E).

Because sEH inhibition is associated with salutary effects, we next assessed the metabolic actions of t-TUCB in mice with HFD-induced obesity. As shown in Fig. 3A, t-TUCB did not modify weight gain in WT mice or alter the resistance of fat-1 mice to become obese. Consequently, endpoint body weight was only influenced by the fat-1 phenotype (Fig. S6A). Anatomical 7.0T magnetic resonance imaging (MR) analysis confirmed reduced total fat volume in fat-1 mice and absence of changes in this parameter following t-TUCB treatment (Fig. 3B and C and Fig. S6B). Interestingly, interscapular brown adipose tissue (iBAT) volume was increased in fat-1 mice treated with t-TUCB (Fig. 3D and Fig. 3C). Despite the absence of changes in total fat volume, t-TUCB significantly reduced adipocyte hypertrophy, macrophage infiltration, and adipose tissue fibrosis in obese WT mice (Fig. 3E). No further reduction in these adiposity parameters was observed in obese fat-1 mice receiving t-TUCB (Fig. 3E). These findings were confirmed by morphometric analysis and the assessment of F4/80 mRNA expression (Fig. 3E). Changes in adipose tissue fibrosis were also confirmed by Masson’s trichrome staining (Fig. S6D). Of interest, t-TUCB significantly reduced lipid peroxidation in fat-1 mice and up-regulated the expression of MGL1 and RELMα in both WT and fat-1 mice (Fig. 3F).

The effects of t-TUCB on the liver are shown in Fig. 4. t-TUCB effectively blocked HFD-induced hepatic macrophage infiltration in WT mice, an effect that was more intense in fat-1 mice (Fig. 4A). Consistently, t-TUCB decreased hepatic IL-1β and IL-6 expression (Fig. 4B), while up-regulating MGL1 and CD206 (Fig. 4C). M2 polarization of hepatic macrophages was more evident in fat-1 mice receiving t-TUCB (Fig. 4C). In addition to reducing inflammation, t-TUCB decreased the hepatic lipid content and induced a synergistic anti-inflammatory action in fat-1 mice, as detected by MR spectroscopy (Fig. 4D). Representative spectra are depicted in Fig. 4E. The reduction of liver weight in fat-1 mice was not further decreased by t-TUCB (Fig. 4F).

Because dysregulation of autophagy is a critical component of liver and eWAT dysfunction in obesity (20), we next investigated the effects of sEH inhibition on autophagy and the emergence of endoplasmic reticulum (ER) stress, insulin resistance, and lipid deposition in obesity. Consistent with previous studies (21, 22), HFD-induced obesity increased the activity of the molecular indicators of autophagy, Atg12-Atg5 and LC3-II, in eWAT from WT mice (Fig. 5A and B). No changes in Atg12-Atg5 and LC3-II conjugates were observed in fat-1 mice after HFD feeding, but LC3-II was reduced and p62 was increased by t-TUCB (Fig. 5A and B). On the other hand, in livers from WT mice, HFD-induced obesity was associated with reduced Atg12-Atg5 and LC3-II levels, and these markers of autophagy were restored by t-TUCB treatment (Fig. 5 C and D). Reduced autophagy was not observed in livers from fat-1 mice, suggesting that these mice were already protected from HFD-induced autophagy dysfunction (Fig. 5 C and D). Taken together, and considering that Atg12-Atg5 and LC3-II conjugates are required for autophagosome formation and that the induction of p62 levels indicates a lack of functional autophagic degradation (23), our data suggest that sEH inhibition improves the autophagy flux in obese insulin-sensitive tissues. Finally, consistently with the view that autophagy is integrated to ER homeostasis (20), t-TUCB administration resulted in reduced ER stress, as shown by the attenuation of inositol-requiring enzyme 1α (IRE-1α) and eukaryotic initiation factor 2α (eIF2α) phosphorylation in both eWAT and liver (Fig. 5 A and C). The extent of suppression of ER stress by t-TUCB was roughly similar in WT and fat-1 mice (Fig. 5 A and C).
In vitro effects of EpFA on autophagy, ER stress, and lipid accumulation in primary hepatocytes. (A) Western blots (15% SDS/PAGE) of Atg7, Atg12-Atg5, LC3-I, LC3-II, eIF2α, p-eIF2α, total eIF2α (eIF2α), and α-tubulin in hepatocytes incubated with vehicle or palmitate (PA) (0.5 mM) in combination with 19,20-EDP (1 μM) and t-TUCB (1 μM) in the absence or presence of E-64depestatin A for 24 h. (B) Representative photomicrographs of visible microscope (Top) and Oil Red-O-stained (Middle and Bottom) hepatocytes exposed to vehicle or PA alone or in combination with 19,20-EDP (EDP) and t-TUCB for 24 h. The amount of Oil Red-O retained is shown on the right. (C) Representative photomicrographs of Oil Red-O-stained hepatocytes exposed to either vehicle or PA alone or in combination with 17,18-EEQ (EEQ, 1 μM), 14,15-EET (EET, 1 μM), DHA (1 and 10 μM), and t-TUCB (1 μM) for 24 h. (D) Western blot analysis of Atg7, Atg12-Atg5, LC3-I, LC3-II, p62, p-eIF2α, total eIF2α, eIF2α, and α-tubulin in hepatocytes incubated with the same conditions as in C. (E) Protein expression of LC3-II, p62 and α-tubulin in hepatocytes incubated with vehicle or PA in combination with 17(S)-HDHA (1 μM). (F) Amount of Oil Red-O retained by hepatocytes in response to PA and 17(S)-HDHA. Results are mean ± SEM from four independent experiments assayed in triplicate. *P < 0.01 and **P < 0.001 vs. vehicle. a, P < 0.05 vs. PA. (Magnification: 200×).

To provide direct evidence linking omega-3 EpFA to autophagy and ER stress, we next performed in vitro experiments in adipocytes incubated with the saturated fatty acid palmitate, a major contributor to lipotoxicity and insulin resistance (24). A schematic diagram of the experimental in vitro procedure is shown in Fig. 6A. Incubation of adipocytes with 19,20-EDP, the most abundant omega-3 epoxide in eWAT, in the presence of t-TUCB, stimulated glucose uptake in adipocytes (Fig. 6B). Moreover, in these cells, 19,20-EDP and 17,18-EEQ induced a concentration-dependent up-regulation of insulin receptor substrate-1 (IRS-1) and glucose transporter-type 4 (GLUT-4) (Fig. 6C). Interestingly, in the presence of t-TUCB, both 19,20-EDP and 17,18-EEQ produced similar changes in autophagy to those reported in vivo in eWAT from obese fat-1 mice receiving t-TUCB (Fig. 6D). With t-TUCB on board, reduction of IRE-1α and eIF2α phosphorylation in response to these omega-3 EpFA also paralleled that seen in vivo (Fig. 6D). In these experiments, the omega-6 EpFA, 14,15-EET, and the non-oxidized form of DHA were either ineffective or less active than omega-3 EpFA in regulating autophagy and ER stress in adipocytes (Fig. 6E). All compounds tested significantly reduced palmitate-induced accumulation of lipids in adipocytes, with the EpFA being more potent than the non-oxidized form of DHA (Fig. 6F). t-TUCB alone did not modify ER stress, autophagy, and intracellular lipid levels (Fig. S6E).

Finally, we incubated hepatocytes with palmitate in the presence of EpFA and t-TUCB. As shown in Fig. 7A, incubation of hepatocytes with 19,20-EDP and t-TUCB resulted in increased autophagosome formation, as revealed by the disappearance of LC3-I and its conversion to LC3-II by conjugation to phosphatidylethanolamine. This improvement in autophagy was mirrored by a reduction in the phosphorylated forms of IRE-1α and eIF2α, indicative of attenuated ER stress in hepatocytes (Fig. 7A). In these cells, 19,20-EDP also overrode palmitate-induced accumulation of intracellular lipids (Fig. 7B). Similar actions on intracellular lipid levels were observed with 17,18-EEQ as well as with DHA and 14,15-EET, although this omega-6 EpFA was less potent than the omega-3 epoxides (Fig. 7C). However, compared with 19,20-EDP, 17,18-EEQ, DHA, and 14,15-EET were less active in regulating autophagy and unable to modulate ER stress in hepatocytes (Fig. 7D). Finally, we explored the effects of 17(S)-HDHA, a lipid mediator acting as a precursor and marker of the biosynthesis of the D-series resolvins and protectins derived from DHA through the lipoxigenase pathway (16). This hydroxylated DHA-derived product also enhanced autophagy in palmitate-treated hepatocytes (Fig. 7E), and reduced the accumulation of intracellular lipids in palmitate-treated hepatocytes (Fig. 7F). t-TUCB alone did not induce any change in the response of hepatocytes to palmitate (Fig. 7B and D).

**Discussion**

Special attention has been given to the effects of omega-3 PUFA on the chronic “low-grade” inflammatory state driven by the expansion of adipose tissue mass in obesity (15, 25). This persistent inflammation in adipose tissue of obese individuals is deleterious and increases the incidence of comorbidities, including insulin resistance and nonalcoholic fatty liver disease, a condition in which a recent systematic meta-analysis reported the benefits of omega-3 PUFA therapy (26). In addition, our understanding the recognized therapeutic values of omega-3s has been challenged by the discovery that these fatty acids can be converted to a novel class of proresolving lipid mediators (i.e., resolvins, protectins, and maresins) (reviewed in ref. 16). Indeed, these proresolving mediators are able to counteract inflammation and to prime the resolution process in obesity-induced nonalcoholic fatty liver disease (17). A common feature of these proresolving lipid mediators is that their biosynthesis from omega-3 PUFA is initiated through the interaction of lipoxigenase and cyclooxygenase pathways, the two classic branches of PUFA metabolism (16). Recent findings indicate that CYP epoxygenases, the so-called third branch of PUFA metabolism, can also convert omega-3 PUFA into bioactive lipid mediators (1, 4, 5). Indeed, CYP1A1, CYP2E1, and CYP2U1 have been described to generate a number of CYP-derived epoxides (namely EEOs and EDPs) from omega-3 PUFA (4). In our study, we used fat-1 mice as an optimal model of omega-3 enrichment, in which the stabilization of CYP-derived epoxides by a sEH inhibitor reinforced the omega-3-dependent reduction in hepatic inflammation and intraplate lipid deposition. Taken together, our findings expand to the metabolic field the initial observation that an omega-3-rich diet in combination with a sEH inhibitor exerts antiinflammatory actions (27). A salient feature of our study was that the sEH inhibitor restored autophagy in livers from obese fat-1 mice. Defective autophagy contributes to a variety of diseases, because efficient sequestration and clearance of damaged cellular components in stress conditions is crucial for cell homeostasis (27). Moreover, consistent with the view that autophagy is a primordial cellular...
adaptive mechanism that mitigates ER-associated unfavorable conditions in insulin-sensitive tissues (20). sEH inhibition in fat-1 mice was accompanied by an attenuated hepatic ER stress. Down-regulation of ER stress was also seen in conjunction with decreased autophagy in adipose tissue from fat-1 mice receiving the sEH inhibitor, suggesting dissociation between these two cellular processes in this tissue. Because inhibition of autophagic function in adipose tissue is related to reduced fat mass and improved insulin sensitivity (28), our findings in adipose tissue can be regarded as beneficial in terms of lipid homeostasis and metabolic control. A strong asset of our study was that we were able to recapitulate the effects on autophagy and ER stress seen in vivo following sEH inhibition, by exposing hepatocytes and adipocytes in vitro to the omega-3 epoxides 19,20-EDP and 17,18-EEQ. Our findings are consistent with those reported by Bettaieb et al., who showed attenuation of ER stress in adipose and liver tissues in mice either receiving a sEH inhibitor or deficient for sEH (29). However, our data cannot exclude other EpFA, such as the case of arachidonic acid-derived EETs as well as the potential implication of other oxidized lipid mediators derived from omega-3 PUFA through the interaction of lipoxygenase and cyclooxygenase pathway. Additionally, our data cannot exclude the potential implication of nonoxidized DHA in the observed favorable metabolic phenotype of fat-1 mice. In this regard, although less potent than EpFA, DHA was active in our cell bioassays. This finding is consistent with the reported biological properties of DHA (30) and with findings reported by Caviglia et al. showing that DHA was able to rescue rat hepatoma cells from palmitate-induced ER stress (31). However, these studies did not address whether the protective effects of DHA were mediated by the parent nonoxidized molecule or by any other DHA oxidized metabolite (30, 31).

In summary, the results of the present study demonstrate that stabilization of omega-3 epoxides through inhibition of sEH exerts beneficial actions in counteracting the metabolic disorders associated with obesity. Of particular interest are the findings demonstrating the ability of sEH inhibition to restore autophagy in the liver with the consequent reduction of obesity-induced liver ER stress. Our observations highlight the potentiality of small bioactive lipid mediators to modulate autophagy, serving as templates for the exploitation of this housekeeping cellular process for therapeutic interventions against obesity and obesity-related comorbidities, such as fatty liver disease.

Materials and Methods

Studies in fat-1 mice, hepatocytes and 3T3-L1 adipocytes, measurement of 2-deoxyglucose uptake, mRNA and protein expression, and histology and immunohistochemistry analysis, MR imaging and spectroscopy, and LC-ESI-MS/MS and gas chromatography analysis are described in detail in SI Materials and Methods. The LC-MS/MS conditions used to profile the omega-3 and omega-6 epoxides are described in Table S2 and a schematic diagram of the experimental design of the study can be found in Fig. S7.

ACKNOWLEDGMENTS. We thank Dr. J. X. Kang (Massachusetts General Hospital) for kindly providing fat-1 mice, Dr. M. Cofan for gas chromatography analysis, and Anabel Martinez-Puchol for assistance. This work was conducted at the Centre Esther Koplowitz and was supported by Spanish Ministerio de Economía y Competitividad (MEC) (SAF12/32789 and PIE14/000405); the Research Investments in the Sciences and Engineering Program of the University of California, Davis; Grants R01 ES02710 and P42 ES004699 from the National Institute of Environmental Health Sciences; fellowships from MEC (to V.G.-A. and B.R.); Marie Curie Action (A.L.) and an Emili Letang fellowship (to J.A.-Q.). Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas is funded by the Instituto de Salud Carlos III. C.-L.-V. was supported by the Institut d'investigacions Biomèdiques August Pi i Sunyer/ Fundació Clinic.